Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing all right, under the circumstances, but as the saying goes, we are taking one day at a time. We are, after all, looking at months of challenges, but as the Morning Mayor used to say: Every day should be unwrapped like a precious gift. So while you tug on the ribbon, please join us for a delicious cup of stimulation. For those tracking this sort of thing, we have reached for maple bourbon this morning. Meanwhile, here are some tidbits to get you started. Stay safe.

A study of mild to moderate Covid-19 patients in China who were given remdesivir, the Gilead Sciences (GILD) experimental drug, was suspended, according to analysts at RBC Capital Markets, citing updated information on ClinicalTrials.gov. The reason cited was poor enrollment. This comes after a study in severe patients was recently ended for similar reasons. The mild-moderate study had planned to enroll 308 patients from Wuhan, China.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.